results from a regional patient group from the county of Copenhagen

Similar documents
Incidence and Prevalence of Ulcerative Colitis and Crohn's Disease in the County of Copenhagen, 1962 to 1978

Mortality in Ulcerative Colitis

Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

INFLAMMATORY COLON DISEASE IN ROCHESTER, MINNESOTA,

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

Colorectal cancer surveillance in inflammatory bowel diseases

Inflammatory bowel disease and tobacco smoke

IBD high risk groups

St Mark's Hospital from 1953 to 1968

The variable risk of colorectal cancer in patients with inflammatory bowel disease.

ulcerative colitis Some aspects of the epidemiology of Progress report stoma.' This review examines epidemiological data which may give some

Ileo-rectal anastomosis for Crohn's disease of

Proctocolitis and Crohn's disease of the colon:

Prognosis after Treatment of Villous Adenomas

Original articles. Prognosis and management of Crohn's disease in the over-55 age group. 1960,' and its distinction from ischaemic

PROFILE OF ULCERATIVE COLITIS IN SOUTH INDIAN REGION: KARAIKAL D.BADMAPRIYA*, V.SATHISH KUMAR 1

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

Persistence of mucosal abnormality in ulcerative colitis

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

IBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital

Crohn's disease: natural history and treatment J. E. LENNARD-JONES. College and St Mark's Hospitals, London

Patients With Ulcerative Colitis Miss More Days of Work Than the General Population, Even Following Colectomy

Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis

Crohn's disease in Blackpool

Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Implementation of disease and safety predictors during disease management in UC

Value of sigmoidoscopy and biopsy in detection of

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

The course and prognosis of ulcerative colitis

Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma?

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Estimation of carcinoembryonic antigen in ulcerative colitis with special reference to malignant

Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema

Crohn's disease in Northern Ireland

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

Ali Keshavarzian MD Rush University Medical Center

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Long-term prognosis of children with ulcerative colitis

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Which is the Safest Strategy to Treat Moderate to Severe IBD?

Crohn's Disease in the Jewish Population of Tel-A viv-yafo

Psoriasis is associated with increased risk of incident Diabetes Mellitus: A Danish nationwide cohort study

Disease behavior in adult patients- are there predictors for stricture or fistula formation?

Diagnostic techniques for surveillance of dysplasia

T he treatment strategy for Crohn s disease (CD) is

How to differentiate Segmental Colitis Associated with Diverticulosis and Inflammatory Bowel Diseases?

Protocol for the management of acute severe ulcerative colitis in children

The incidence of ulcerative colitis ( ) and Crohn's disease ( ) Based on nationwide Danish registry data

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

Diabetologia 9 Springer-Verlag 1983

Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv

Predicting outcome in severe ulcerative colitis

Related Media. Dr. Rubin discusses smoking as a trigger (00:00, MP3 xx MB)

Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort

GUIDANCE ON THE INDICATIONS FOR DIAGNOSTIC UPPER GI ENDOSCOPY, FLEXIBLE SIGMOIDOSCOPY AND COLONOSCOPY

Chronic ulcerative colitis: incidence and prevalence in a community

Toward optimal use of corticosteroids in

Lack of Association Between Smoking and Inflammatory Bowel Disease in Jewish Patients in Israel

Measurement of colonic transit time with the Transit-Pellets TM method

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Doncaster & Bassetlaw Medicines Formulary

Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura

Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis Provenzale D, Wong J B, Onken J E, Lipscomb J

East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

GRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM

Crohn's disease. Appendix N. Clinical Guideline < > 10 October Surgery recurrence rates

ORIGINAL ARTICLE. A New Scoring System to Evaluate and Predict Outcome of Surgical Intervention

Convegno Annuale Fondazione Rosa Gallo. Risultati chirurgici a lungo termine nelle IBD John Nicholls

ULCERATIVE COLITIS FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS

ULCERATIVE COLITIS FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS

Prevention of Bowel Cancer: which patients do I send for colonoscopy?

complicating inflammatory bowel disease

Toxic megacolon in ulcerative colitis: a continuing challenge

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

THE NATURAL HISTORY OF 271 PATIENTS WITH MITRAL STENOSIS UNDER MEDICAL TREATMENT

Research Article Temporary Fecal Diversion in the Management of Colorectal and Perianal Crohn s Disease

Systematic review: the costs of ulcerative colitis in Western countries

An Investigation into the Validity of the Present Classification of Inflammatory Bowel Disease

Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?

embedded tissue-sections has the advantage of permanence of the sections and is more suitable for

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery

Diagnostic difficulty arising from rectal recovery

Colectomy. Surgical treatment for Ulcerative Colitis (UC) and Familial Adenomatous Polyposis (FAP) Patient and Family Education

Inflammatory Bowel Disease and Surgery: What You Should Know

Spectrum of Diverticular Disease. Outline

Adult organisational audit

5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease

Objec-ve. Case Presenta-ons and Ques-ons to Panel. Dysplasia case 11/13/11

Blood eosinophilia and ulcerative colitis - influence of ethnic origin

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

Positioning Biologics in Ulcerative Colitis

A. Green, C. Sortsø, P.B. Jensen, M. Emneus

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Transcription:

Gut, 1985, 26, 158-163 Long term prognosis in ulcerative colitis based on results from a regional patient group from the county of Copenhagen C HENDRIKSEN, S KREINER, AND V BINDER From the Medical-Gastroenterological Department C, Herlev Hospital, University of Copenhagen, Denmark SUMMARY The prognosis of ulcerative colitis including survival, colectomy rate, activity of disease, and working capacity was estimated from a follow up study of 783 patients with ulcerative colitis comprising all patients from the county of Copenhagen, except for the island of Amager, diagnosed between 1960 and 1978. The period of observation ranged from one to 18 years with a median of 6-7 years for the clinical observations, eight years for survival and 11.6 years for the occurrence of large bowel cancer. The follow up was 100% for both survival and cancer. The survival rate in women did not differ from that in the general population. In men over 40 years of age at diagnosis a slight excess mortality was found, but only in the year of diagnosis (2 1%) and the following year (1.5%). Colonic cancer was seen in only seven out of the 783 patients, corresponding to an annual risk of 0'07% and a cumulative risk after 18 years with ulcerative colitis of 1-4% (95% confidence limits, 0 7-2-8%) independent of the initial extent of disease. The colectomy rate was 9-6% in the year of diagnosis. The cumulative 10- and 18-year colectomy rate was 23% and 31%, respectively. After three years from diagnosis the capacity for work both in those subject to resection and treated conservatively did not differ significantly from that in the background population. At any time about 50% of the patients were without symptoms, in about 30% the disease activity was low and in about 20% moderate or high. Most patients, however, differed in activity from one year to another and almost all patients (97%) experienced at least one relapse during a 10 year time period. 'T'he impact of a chronic disease on the life of the individual depends on three major factors: the premorbid state of the patient (age, intellectual condition, physical condition, etc), the course of the disease (intermittent or continuous, high or moderate activity, etc), and the efficacy and type of treatment. These factors combined determine the prognosis of the disease in terms of survival as well as in measurement of the quality of life. The aim of the present study was to evaluate the prognosis of ulcerative colitis on the basis of survival, working capacity, colectomy rate, activity and course of disease, and thereby attempt to answer the inevitable question from the newly diagnosed patient: 'How will the disease influence my life in the future?' Address for correspondence: V Binder, Hospital, DK-2730 Herlev, Denmark. Medical Department C, Herlev Received for publication 9 May 1984 Long term follow up studies of all cases within a sufficiently large region are a prerequisite for the study of the prognosis of a specific chronic disease. All patients with ulcerative colitis in the county of Copenhagen have been followed regularly since 1960. The results form the basis of the present work. Methods PATIENTS BACKGROUND POPULATION The background area was the county of Copenhagen except for a small part on the Island of Amager. The region comprises the outskirts of central Copenhagen with a population of 433 043 in 1960 and 573 237 in 1978 - more than 10% of the total Danish population. The national health system provides free medical care including sick day pay. Thus, no patient has to abstain from treatment for economic reasons. 158

Prognosis in ulcerative colitis STUDY POPULATION In total 783 patients, 342 men and 441 women, who were residents of the county of Copenhagen, fulfilled the diagnostic criteria of ulcerative colitis during the period 1960-1978. The diagnostic criteria and a detailed description of the patients have been published.' 2 The median age at diagnosis was 33.0 years for men and 34.4 years for women. Among the patients, 78% were diagnosed and treated in our department, and the remaining 22% attended other hospitals within the area. The principles of diagnosis and treatment were the same, and all clinical data have been made available for -the study. One hundred and twenty four patients (16%) had total colon involvement, 319 (41%) extending beyond the rectum and 318 (41%) only rectal involvement judged radiologically, at the time of diagnosis. CLINICAL FOLLOW UP The patients were reviewed annually or more frequently if symptomatic. An annual assessment was made as to inflammatory activity, working capacity, treatment, and the cancer risk considered. The principles of treatment have been similar throughout the study period as previously described:3 long-term sulphasalazine to prevent relapses; prednisolone locally and/or systemically in short time courses during flare up periods; colectomy in case of failure of medical treatment, including short lasting, intense steroid treatment. Colectomy was also performed in case of a long standing chronic disease requiring frequent or continuous steroid treatment. Colectomy has not been performed as cancer prophylaxis. The patients were followed from the time of diagnosis until 31 December 1978 or until death (67 patients), emigration from the district (92 patients), or termination of follow up by the patient for other personal reasons (106 patients). One hundred and eighty-eight patients (24%) were followed for 11 years or more, 42 patients (5%) for more than 15 years. At the end of the study 512 patients were still under review. The follow up period ranged from one to 18 years (mean 6.7 years). Through the Danish Central Person Register the patients who dropped out during the study were traced as regards survival at the end of the study period, so that all deaths are included in the present survival curves, the median observation period being 8-0 years (mean 7-9 years). Through the Danish Cancer Registry the total group of ulcerative colitis patients was traced until the end of 1982 as regards occurrence of gastrointestinal cancer, yielding a median observation period for this specific variable of 11-6 years (mean 11-6 years). DEFINITIONS Each observation year has been classified according to the following criteria. COURSE OF DISEASE Intermittent: occurrence of symptom-free period(s) of at least one month's duration excluding periods where the patient was in steroid treatment. Continuous: without symptom-free periods. Inactive: completely free of bowel symptoms during the year. Low activity: more than two and not more than four bowel movements per day and/or less than daily occurrence of blood/pus in the stools. No general symptoms such as fever or loss of weight. High activity: more than four bowel movements per day and/or daily occurrence of blood/pus in the stools with or without general symptoms such as fever or loss of weight. CAPACITY FOR WORK The capacity for work was defined by the days lost through sickness, independent of cause. Fully capable: less than one month lost through sickness during the year. Partly capable: one month or more but less than 11 months lost through sickness during the year. Not capable: 11 months or more lost through sickness during the year. STATISTICAL METHODS The risk of death was finally compared with the mortality of the population at large. For each year after diagnosis, the expected number of deaths among the patients at risk was estimated taking into account for each individual both sex, age, and calendar year. The difference between the observed and the expected number of deaths was evaluated on the assumption that the actual number of deaths is distributed according to a Poisson distribution. Results 159 SURVIVAL RATES Patients with ulcerative colitis are shown in Figs. 1 and 2 together with their survival rates of the age-matched background population. In the women the survival did not differ between the patients and the background population at any time. The men had a slightly increased mortality in the year of diagnosis (2-1%) and the following year (1.5%). From the second year after diagnosis the survival did not differ from that of the background population. The extra mortality in the first and the second disease year was only significant in age groups over 40 years at diagnosis.

160 1000-500 Survival - ulcerative colitis - women 72SD i Patients ---- Normals lao. D1 234 5 10 15 after diagnosis Fig. 1 Survival of women with ulcerative colitis compared with the age- and sex-matched background population. RISK OF CANCER This was found to be very low. Only seven of the 783 patients developed colonic cancer during the observation period, and the additional four years from 1979 to the end of 1982. This compares with an annual risk of 0-077% (95% confidence limits, 0.0374-159%). The cumulative risk of developing colonic cancer at 10 years is 0-8%, at 15 years 11%, O/oo........ I... *..... i2sd Patients ---- Normals D1 234 after diagnosis Fig. 2 Survival ofmen with ulcerative colitis compared with the age- and sex-matched background population. Hendriksen, Kreiner, and Binder and at 18 years 1 4% with 95% confidence limits, 0-7-2-8%. The seven cases of cancer are described in details in Table 1. The cumulative risk of developing cancer was not influenced by the initial extent of the colitis. The cumulative risk after 18 years was 1-3% for patients with total colon involvement at the time of diagnosis. COLECTOMY RATE This was estimated for each year after diagnosis (Fig. 3). Ten per cent of the patients had an operation in the year of diagnosis and 3% in the following year. After four years the risk of undergoing colectomy was constant, about 1% per year. In Figure 4 the cumulative colectomy rates are given. A total of 149 patients underwent colectomy during the observation period. ACTIVITY OF DISEASE This was estimated for each separate year after diagnosis (Fig. 5). At any time about 50% of the patients were free of symptoms. The percentage was increased slightly with increasing duration of the disease. Similarly, in about 30% the disease was at any time in low activity and in about 20% in moderate or high activity. Most patients, however, differ in activity from one year to another. The chance of being free of relapses is seen in Figure 6. After 10 years less than 3% and after 18 years less than 1% of the patients had not experienced a relapse. 10* 8- m C A 0. -a 6-0~ 2- U cerative colitis Colectomy rates per year D 2 l 6 8 10 12 14 16 18 Fig. 3 Colectomy rates in different years after the diagnosis of ulcerative colitis.

Prognosis in ulcerative colitis Table 1 Seven cases of colonic cancer among 783 patients with ulcerative colitis Age at cancer Duration from IBD Durationfromfirst Extent of colitis at Localisation of Sex diagnosis (yr) diagnosis (yr) IBD symptom (yr) IBD diagnosis cancer NS M 41 24 24 Substantial part Caecum KW F 74 44 58 All colon Rectum BH M 15 4 12 All colon Sigmoid VO M 69 19 19 Substantial part Rectum BF M 73 13 56 Rectum only Caecum LN F 40 4 9 Substantial part Ascendens MH F 32 17 18 Substantial part Rectum COURSE OF DISEASE This was defined as continuous, intermittent, or inactive - as shown in Figure 7 for each year after diagnosis. About 10% of the patients had a continuous and about 40% an intermittent course. This calculation was based upon unoperated patients only, but included patient years up to the time of operation. A continuous course over several years was rare, and the cumulative probability of such a course is shown in Table 2. The percentage of patients with persistent symptoms fell rapidly during the first few years and was almost zero after 10 years because many of this group underwent colectomy. WORKING CAPACITY This was estimated for all patients in their employable age, shown in Figure 8, for each year after diagnosis. Except for the first few years, about 90% of the patients were fully capable of work. Less than 5% received disablement pension and practically none of them because of their inflammatory bowel disease. Discussion We have previously shown that our patient group In.0 E 20 41 60 Ulcerative colitis a" I Cumulated colectomy rates D 2 4 6 8 lb i2 I4Y 1er8 Fig. 4 Cumulative colectomy rates in the ulcerative colitis patients. comprises more than 99% of all patients in the region who have had the diagnosis of ulcerative colitis made.2 In 16 patients the initial diagnosis of ulcerative colitis appeared later to be Crohn's disease. In six patients the diagnosis was changed during the observation period from Crohn's disease to ulcerative colitis. The patients were included in the present study for all years during which they fulfilled the diagnostic criteria of ulcerative colitis. The follow up was 100% concerning survival and cancer occurrence, since patients who emigrated from the area or dropped out for other reasons were traced at the end of the study via the Danish Central Person Register and Cancer Registry. Additionally the period 1979-1982 was included for cancer occurrence, thus increasing the median observation period to 11.6 years. The clinical results were only obtainable for the years when they attended one of the clinics in the in 100] 80 0 41 Ulcerative colitis Activity of disease 0-- L*Inactive stage x x Low activity Il-oo Highactivity X,-xx_xx D 2 4 6 8 10 O 60-40- 20- _x_x-x-x-x-x-x-x-x- 161 ~~ ~ ~ ~ ~. ~ ~~~~~~,. 12 14 16 18 Fig. 5 Disease activity. Calculations based upon all patients who were alive and conservatively treated.

162 Ut cs 0 0) a 0~ Ulcerative colitis Cumulative relapse-free course Fig. 6 Cumulative course of ulcerative colitis calculated on the basis ofconservatively treated. area. The analyses revealed a stationary course from the fifth year from diagnosis onwards. An analysis was made of the clinical disease activity and course of disease in the year before drop out for those patients who were lost because of emigration from the district or who failed to attend for personal reasons. The analysis showed no difference in the disease activity and course between these patients and those remaining in the study. Thus it seems that the remaining patient group was not skewed. The excellent overall prognosis of ulcerative colitis in this study confirms results previously published from our group for the period 1960-1971,3 and our cancer risk figures are similar to those recorded from Israel.4 Other studies,>'0 however, have shown a more serious prognosis with a higher mortality and a higher cancer risk. The regional and thereby unselected patient group in our study tends to show the true picture of the disease and a better prognosis than in a group of patients selected for 80 j~ 60,w._' CL o 40 c a. & 20- Ulcerative colitis Inactive course ntermittent course Contits course e-x_~~~x X-XK-- D 2 4 6 8 10 12 14 16 18 Fig. 7 Course ofdisease. Calculations based upon all patients who were alive and conservatively treated. Hendriksen, Kreiner, and Binder Table 2 Cumulative course of ulcerative colitis calculated on the basis of unoperated patients only Duration ofdisease (yr) Continuous since start of disease (%) 1 126 2 58 3 32 4 18 5 1-0 10 0-05 15 0.003 18 00 severity. Further patients in this study were treated by a specialist group from onset which presumably will lead to a better prognosis. The therapeutic approach has been active - that is, the patients have been controlled regularly in the outpatient clinic and with rapid admission to hospital in the case of relapse. The possibility that ulcerative colitis may take a less serious course in Denmark seems unlikely, because about 30% of the patients underwent colectomy within the first 18 years. Among the patients treated by colectomy the largest part comprises patients with initial total colon involvement. Since it is known that patients with extensive colitis are at risk for cancer, our therapeutic policy in the first years after diagnosis has reduced the number of patients at risk. to0 80 Ulcerative colitis Capacity for work.t [* * ~~Fully capable ic 6 x x Partly capable 9 11 ~~0--o Incapable 0 4~0 2 4 6 8 10 12 1i' 16 18 Fig. 8 Probability of being capable for work for each separate year. The calculations comprises all patients with ulcerative colitis both medically and surgically treated.

Prognosis in ulcerative colitis 163 As far as the course of disease, the present results are in good agreement with the findings from Leeds"' and London.12 The finding that 90% of the patients were fully capable for work is similar to that in the background population, even if a directly comparable registration of absence from work is not available. In 1981 4.4% of the Danish population between 14 and 66 years received disablement pension,'3 a figure which does not differ from that found in our ulcerative colitis patients. These results on social prognosis are in agreement with a previous study which compared a randomised group of ulcerative colitis patients with an age- and sexmatched control group. 14 The two groups were similar in marital status, the frequency of severe family or sexual problems, leisure activities, physical capacity and earning capacity, the incidence of mental disorders, and intake of alcohol and psychopharmacological drugs. A very recent study from Scotland'5 showed a good prognosis in ulcerative colitis as in the present study with an improving course as the duration of the disease increased. The reported incidence of ulcerative colitis in Scotland is much higher than our own study. Ulcerative colitis has a chronic course, and the inconveniences for operated as well as unoperated patients should not be minimised. It however, appears that with an active therapeutic approach the patients seem to lead a near normal life. This work was supported by the Danish Medical Research Council (Grant No. 12-9080). References 1 Both H, Torp-Pedersen K, Kreiner S, Hendriksen C, Binder V. Clinical appearance at diagnosis of ulcerative colitis and Crohn's disease in a regional patient group. Scand J Gastroenterol 1983; 18: 987-91. 2 Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978. Gastroenterology 1982; 83: 563-8. 3 Bonnevie 0, Binder V, Anthonisen P, Riis P. The prognosis of ulcerative colitis. Scand J Gastroenterol 1974; 9: 81-91. 4 Gilat T, Zemishlany Z, Ribak J et al. Ulcerative colitis in the Jewish population of Tel-Aviv Yafo. II: The racity of malignant degeneration. Gastroenterology 1974; 67: 933-8. 5 Jalan KN, Prescott RJ, Sircus W et al. An experience of ulcerative colitis. III. Long term outcome. Gastroenterology 1970; 59: 598-609. 6 Lennard-Jones JE, Misiewicz JJ, Parrish JA et al. Prospective study of outpatients with extensive colitis. Lancet 1974; 1: 1065-7. 7 Storgaard L, Bischoff N, Henriksen FW et al. Survival rate in Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1979; 14: 225-30. 8 Lanfranchi GA, Brignola C, Michelini M et al. Clinical course of ulcerative colitis in Italy. Digestion 1980; 20: 106-10. 9 Gyde S, Prior P, Dew MJ et al. Mortality in ulcerative colitis. Gastroenterology 1982; 83: 36-43. 10 Gilat T, Lilos P, Zemishlany Z, Ribak J, Benaroya Y. Ulcerative colitis in the Jewish population of Tel-Aviv Yafo. III: Clinical course. Gastroenterology 1976; 70: 14-9. 11 Watts JMcK, de Dombal FT, Watkinson G, Goligher JC. Long-term prognosis of ulcerative colitis. Br Med J 1966; 1: 1447-53. 12 Ritchie JK, Powell-Tuck J, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet 1978; 1: 1140-3. 13 Statistiske efterretninger A28. Danmarks Statistik (Denmark's Central Statistical Agency), 1981. 14 Hendriksen C, Binder V. Social prognosis in patients with ulcerative colitis. Br Med J 1980; 281: 581-3. 15 Sinclair TS, Brunt PW, Mowat NAG. Nonspecific proctocolitis in Northeastern Scotland: a community study. Gastroenterology 1983; 85: 1-11.